This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CNTA

Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis

Centessa Pharmaceuticals logo

About Centessa Pharmaceuticals Stock (NASDAQ:CNTA)

Key Stats

Today's Range
$40.50
▼
$40.50
50-Day Range
$39.62
▼
$40.71
52-Week Range
$12.74
▼
$40.56
Volume
N/A
Average Volume
2.15 million shs
Market Capitalization
$6.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.00
Consensus Rating
Hold

Company Overview

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders. Each affiliated research unit is advancing one or more drug candidates through discovery, preclinical studies and clinical trials. By maintaining strategic agility within its autonomous project teams, Centessa seeks to optimize development timelines and increase the probability of regulatory success.

The company was formed in 2021 through an investment consortium and completed its initial public offering via a business combination with Narwhal Acquisition Corp. in early 2022. Headquartered in Cambridge, U.K., Centessa maintains a significant presence in the United States, with research and development sites located in key biotech hubs. This transatlantic footprint enables collaboration with leading academic institutions and access to diverse clinical trial networks.

Under the leadership of Chief Executive Officer Knut Brundin, Centessa Pharmaceuticals draws on decades of industry experience to guide its strategic vision. The management team is complemented by veteran drug developers, regulatory experts and academic advisors, all committed to advancing novel therapies from laboratory research to patient care.

AI Generated. May Contain Errors.

Receive CNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CNTA Stock News Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
Centessa Pharmaceuticals plc (CNTA)
See More Headlines

CNTA Stock Analysis - Frequently Asked Questions

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) released its quarterly earnings results on Tuesday, March, 31st. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.10.

Centessa Pharmaceuticals (CNTA) raised $314 million in an initial public offering on Friday, May 28th 2021. The company issued 16,500,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Centessa Pharmaceuticals investors own include Palantir Technologies (PLTR), CrowdStrike (CRWD), Intuitive Surgical (ISRG), Pfizer (PFE), Arista Networks (ANET), Advanced Micro Devices (AMD) and ASML (ASML).

Company Calendar

Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CNTA
CIK
1847903
Fax
N/A
Employees
200
Year Founded
2021

Price Target and Rating

High Price Target
$62.00
Low Price Target
$30.00
Potential Upside/Downside
+3.7%
Consensus Rating
Hold
Rating Score (0-4)
2.21
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$197.53 million
Net Margins
N/A
Pretax Margin
-1,304.75%
Return on Equity
-60.37%
Return on Assets
-44.17%

Debt

Debt-to-Equity Ratio
0.23
Current Ratio
9.53
Quick Ratio
9.53

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.92 per share
Price / Book
10.33

Miscellaneous

Outstanding Shares
154,731,000
Free Float
148,403,000
Market Cap
$6.27 billion
Optionable
Optionable
Beta
1.11

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:CNTA) was last updated on 6/25/2026 by MarketBeat.com Staff.
From Our Partners